Focus on skin cancer association and progression under TNF antagonist therapy.
about
Malignancy risk of anti-tumor necrosis factor alpha blockers: an overview of systematic reviews and meta-analyses.Stopping, continuing, or restarting immunomodulators and biologics when an infection or malignancy develops.Tumour necrosis factor inhibitors in the treatment of psoriatic arthritis: a view on effectiveness, clinical practice and toxicity.Malignancies in children and young adults on etanercept: summary of cases from clinical trials and post marketing reports.
P2860
Focus on skin cancer association and progression under TNF antagonist therapy.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 16 July 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Focus on skin cancer association and progression under TNF antagonist therapy.
@en
Focus on skin cancer association and progression under TNF antagonist therapy.
@nl
type
label
Focus on skin cancer association and progression under TNF antagonist therapy.
@en
Focus on skin cancer association and progression under TNF antagonist therapy.
@nl
prefLabel
Focus on skin cancer association and progression under TNF antagonist therapy.
@en
Focus on skin cancer association and progression under TNF antagonist therapy.
@nl
P2093
P2860
P1476
Focus on skin cancer association and progression under TNF antagonist therapy.
@en
P2093
Claudine Piérard-Franchimont
Gérald E Piérard
Pascale Quatresooz
P2860
P304
P356
10.1517/14712598.2011.582463
P407
P577
2011-07-16T00:00:00Z